CEO: Chandrabali Ghose, PhD

Visit Website

Antimicrobial resistance is a serious and growing problem in infectious disease. Bioharmony’s portfolio consists of lysins to treat pneumonia, skin, urinary tract, and bloodstream infections caused by Gram-negative bacterial infections. Bioharmony has partnered with Boehringer Ingelheim to develop lysins to treat multidrug- resistant (MDR) Acinetobacter infections, a common cause of hospital-acquired pneumonia and life-threatening blood or wound infections.